Ado-trastuzumab emtansine led to improved overall survival and invasive disease–free survival over trastuzumab in patients ...

Dr. Debu Tripathy discusses the FDA approval of Enhertu in unresectable or metastatic hormone receptor HR+, HER2-low or -ultralow breast cancer.

The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has ...

Shares of solid tumor concern Zymeworks Inc. have barely budged since the company obtained its first approval. Click here to read why ZYME stock is a Hold.

Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...

Shanghai Henlius Biotech, Inc. (“Henlius”) announced FDA acceptance of the Biologics License Application (BLA) for ...

The Micro Immune Response On chip (MIRO) allows tumours and their environment to be replicated in order to understand their response to immunotherapy-based treatments. The device, which has already ...

The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...